For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of this treatment and Tafamidis meglumine represents a true breakthrough . These novel therapies stabilize the transthyretin protein, slowing its harmful build-up and alleviating the